Corporate Update

Funding from European Community approved for collaborative research program between BIOGENERA SpA and University of Padua

Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua. The research program aims to develop a new, unique […]

Read More…

Corporate Update

New operating unit of BIOGENERA SpA in Paris in the prestigious Paris Saclay Cancer Cluster (PSCC)

BIOGENERA SpA is in the process of finalizing the establishment of a new operating unit of the Company in Paris. After a period of careful evaluation for the most appropriate choice, the final decision was made for the Paris Saclay Cancer Cluster (PSCC)(https://www.parissaclaycancercluster.org). The Paris Saclay Cancer Cluster is located in Paris, in the Villejuif […]

Read More…

Corporate Update

A New Goal for Biogenera: BGA002, the Future of Cancer Therapy

The Biogenera team has achieved a major breakthrough in the development of the innovative anti-tumor drug BGA002: a revolutionary drug that targets aggressive tumors in both children and adults, specifically targeting cancer cells and sparing healthy ones. An Innovation in the Fight Against Cancer. New scientific data show that BGA002 is able to penetrate and […]

Read More…

sono io il template